What’s Propelling Stellar Biotechnologies Incorporated (NASDAQ:SBOT) After Lower Shorts Reported?

February 19, 2018 - By Henry Gaston

 What’s Propelling Stellar Biotechnologies Incorporated (NASDAQ:SBOT) After Lower Shorts Reported?

The stock of Stellar Biotechnologies Incorporated (NASDAQ:SBOT) registered a decrease of 6.93% in short interest. SBOT’s total short interest was 53,700 shares in February as published by FINRA. Its down 6.93% from 57,700 shares, reported previously. With 27,000 shares average volume, it will take short sellers 2 days to cover their SBOT’s short positions. The short interest to Stellar Biotechnologies Incorporated’s float is 0.7%.

The stock decreased 4.75% or $0.04 during the last trading session, reaching $0.8. About 14,888 shares traded. Stellar Biotechnologies, Inc. (NASDAQ:SBOT) has declined 60.19% since February 19, 2017 and is downtrending. It has underperformed by 76.89% the S&P500.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein primarily in Europe, the United States, and Asia. The company has market cap of $8.42 million. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. It currently has negative earnings. The firm offers its KLH protein under the Stellar KLH brand.

More notable recent Stellar Biotechnologies, Inc. (NASDAQ:SBOT) news were published by: Marketwired.com which released: “Stellar Biotechnologies’ Announces Effective Date of TSX-V Voluntary Delisting” on March 29, 2016, also Seekingalpha.com with their article: “Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships” published on June 23, 2016, Prnewswire.com published: “Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology” on March 13, 2017. More interesting news about Stellar Biotechnologies, Inc. (NASDAQ:SBOT) were released by: Marketwatch.com and their article: “Stellar Biotechnologies Inc.” published on August 01, 2016 as well as Marketwired.com‘s news article titled: “The Life Sciences Report Examines Stellar Biotechnologies (SBOT:NASDAQ) Inking …” with publication date: March 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.